Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

MLA

Fraser, Graeme A. M., et al. “Final 5-Year Findings from the Phase 3 HELIOS Study of Ibrutinib plus Bendamustine and Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” Leukemia & Lymphoma, vol. 61, no. 13, Dec. 2020, pp. 3188–97. EBSCOhost, https://doi.org/10.1080/10428194.2020.1795159.

APA

Fraser, G. A. M., Chanan-Khan, A., Demirkan, F., Santucci Silva, R., Grosicki, S., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M.-S., Loscertales, J., Avigdor, A., Rule, S., Samoilova, O., Pavlovsky, M. A., Goy, A., Mato, A., Hallek, M., Salman, M., Tamegnon, M., & Sun, S. (2020). Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & Lymphoma, 61(13), 3188–3197. https://doi.org/10.1080/10428194.2020.1795159

Chicago

Fraser, Graeme A.M., Asher Chanan-Khan, Fatih Demirkan, Rodrigo Santucci Silva, Sebastian Grosicki, Ann Janssens, Jiri Mayer, et al. 2020. “Final 5-Year Findings from the Phase 3 HELIOS Study of Ibrutinib plus Bendamustine and Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” Leukemia & Lymphoma 61 (13): 3188–97. doi:10.1080/10428194.2020.1795159.